**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was done. Co-authors will be added in a separate section.**
David W. Polston, MD
Cleveland Clinic
Cleveland, OH

**Main Body of the Abstract**
BACKGROUND: Amyloidosis can present in a myriad of ways initially with non-specific symptoms, sometimes leading to delayed or initially incorrect diagnosis.  Neurologically, subacute presentations can potentially be confused with other conditions including AIDP or CIDP.  We present two such cases (AL and TTRv).
METHODS: Two patients with subacute onset of sensory and motor deficits were evaluated. Both had prior history of chronic stable distal lower limb sensory symptoms for 2 or more years attributed to other conditions.
RESULTS:   Both patients were admitted to the hospital for concern of either AIDP or CIDP. Electrophysiological studies suggested a severe subacute on chronic axon loss polyradiculoneuropathy pattern in both patients. No demyelinating features were noted. Both had CSF protein elevation.
The subacute decline and clinical findings lead to consideration of immune therapy use for both.
One previously healthy patient had fatigue and weight loss and mild lambda light chain elevation. Nerve biopsy was obtained. Immune therapy tried empirically without benefit. Biopsy subsequently positive for amyloid deposition.
The other patient had a history of atrial fibrillation, CHF, spinal surgery and bilateral carpal tunnel syndrome, leading to cardiac PYP scan consistent with TTR amyloid. Immune treatment deferred.  TTR gene testing subsequently positive.
CONCLUSION:  These cases illustrate the potential for a subacute neurological presentation of both AL and TTRv amyloidosis. Increasing clinical awareness of this type of presentation may expedite correct diagnosis, treatment initiation and avoidance of therapies ineffective for amyloidosis.



Subacute Axonal Polyradiculoneuropathy Presentation in AL and TTRv Amyloidosis PA76 (#419)

We invite you to attend the XIX International Symposium on Amyloidosis to be held in Rochester, MN.

This symposium is organized as a hybrid meeting (with the focus on in-person) held from Sunday, May 26 through Thursday, May 30, 2024.

Together with the ISA Board and members of Mayo Clinic, a very attractive scientific hybrid program is being planned. The program will cover a variety of types of systemic amyloidosis: ATTR (hereditary and wild-type), AL (light-chain), AA and less frequent forms. There will be key lectures, specific symposia including those company sponsored, oral presentations and poster sessions of accepted abstracts.

COURSE DESCRIPTION
This program will provide a comprehensive review of state-of-the-art education in systemic amyloidosis: basic science, pathophysiology, diagnosis, current and emerging treatments. Scientific presentations will include competitive oral and poster abstracts. The rapid evolution of scientific discovery and expanding treatment options has created tremendous interest in the field and this meeting will fill and important gap in educating scientists and clinicians.